Development of Gene Therapies

ISBN-13: 9781032136554 / Twarda / 2024 / 488 str.

Opis

Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development.

Spis treści

1. Introduction: The Road to Gene Therapy  2. Driving AAV Drug Design to the Right Place, Right Amount, and Right Time  3. A Practical Guide to the Nonclinical Development of In Vivo Gene Therapies  4. Quantitative Systems Pharmacology Modeling of Adeno-Associated Virus Gene Therapies: Mechanistic Identification of Species-Translation Using Preclinical and Clinical Data  5. Bringing Gene Therapy to Patients: A Clinical Development Perspective Based on Brain and Neuromuscular Diseases  6. The Ethics of Gene Therapy  7. AAV Vector Immunogenicity in Gene Therapy: Mechanisms, Assessment, and Immunomodulation Strategies  8. Prenatal Somatic Cell Gene Therapy  9. Development of Gene Therapies for Ultra-Rare Disease  10. Statistical Innovation for Gene Therapy Development: Clinical Trial Design and Analysis Considerations  11. Biomarkers in Gene Therapy Development for Rare Diseases  12. Manufacturing, Analytical, and Process Comparability Challenges for Recombinant Adeno-Associated Virus (rAAV) Gene Therapy  13. Regulatory Considerations in the Development of Gene Therapy Products  14. Gene Therapy Clinical Safety Considerations: Short- and Long-Term  15. Development of Gene Therapies from an Academic Perspective  16. Commercial Models, Access Hurdles, and Health Economics of Gene Therapies  17. The Zolgensma Journey: A Groundbreaking Therapy for SMA  18. History and Development Story of Luxturna: Scientific and Regulatory Challenges  19. The Future of in vivo rAAV Gene Therapies for Rare Neurological Diseases

O autorze

Avery McIntosh, Ph.D. is a drug developer working in rare diseases at Pfizer. He received his M.Sc. and Ph.D. in biostatistics from Boston University with a dissertation on Bayesian methods to model household tuberculosis transmission. He has managed teams of statisticians across study phases and in a variety of drug types and disease areas, including neurology, ophthalmology, infectious disease/ global health, hematology, and oncology. He has published peer-reviewed articles on various topics in drug development and biostatistics, including development of cell and gene therapies and qualification of digital endpoints in neurological diseases.

Oleksandr Sverdlov, Ph.D. is a Neuroscience Disease Area Statistical Lead at Novartis. He received B.Sc. in Applied Mathematics from V.N. Karazin Kharkiv National University, Ukraine, M.Sc. in Statistics from University of Maryland, Baltimore County (UMBC), and Ph.D. in Information Technology with Concentration in Statistical Science from George Mason University. He has been actively involved in methodological research and applications of innovative statistical approaches in drug development. He has co-authored over forty refereed articles, edited two monographs, and co-authored a book ``Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach'' (CRC Press/Chapman \& Hall, 2019). His most recent work involves design and analysis of clinical trials evaluating novel digital technologies.